Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | DRD3 | P35462 | 9/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035223 | 0.84 | DRD2 (0.45) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL740978 | 0.84 | MAPK1 (0.36) | MAPK1DRD2DRD3 | |
| SCHEMBL741316 | 0.83 | MAPK1 (0.45) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL17613234 | 0.73 | DRD2 (0.50) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL13937962 | 0.72 | MAPK1 (0.47) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL7771022 | 0.71 | — | — | |
| SCHEMBL12363792 | 0.71 | DRD2 (0.66) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL741598 | 0.70 | MAPK1 (0.58) | MAPK1GRM5 | |
| SCHEMBL740929 | 0.70 | MAPK1 (0.44) | MAPK1DRD2DRD3FGFR1FGFR2 | |
| SCHEMBL13165535 | 0.69 | PDE10A (0.42) | MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | MAPK1 2378/4885DRD2 214/4885DRD3 226/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | MAPK1 1064/4885DRD2 2312/4885DRD3 1927/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | MAPK1 1349/4885DRD2 702/4885DRD3 713/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | MAPK1 1349/4885DRD2 702/4885DRD3 713/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | MAPK1 987/4885DRD2 294/4885DRD3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.